These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 14973307)

  • 21. A randomized, open-label pharmacokinetic comparison of two oral formulations of fluconazole 150 mg in healthy adult volunteers.
    Jovanović D; Kilibarda V; Cirić B; Vucinić S; Srnić D; Vehabović M; Potogija N
    Clin Ther; 2005 Oct; 27(10):1588-95. PubMed ID: 16330294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
    Rodríguez CA; Azie NE; Adams G; Donaldson K; Francom SF; Staton BA; Bombardt PA
    J Clin Pharmacol; 2004 Mar; 44(3):276-83. PubMed ID: 14973308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics of subcutaneously injected Bimosiamose disodium in healthy male volunteers.
    Meyer M; Beyer D; Vollhardt K; Woischwill C; Jilma B; Wolff G
    Biopharm Drug Dispos; 2007 Dec; 28(9):475-84. PubMed ID: 17876866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluconazole serum concentrations and pharmacokinetics in an obese patient.
    Cohen LG; DiBiasio A; Lisco SJ; Hurford WE
    Pharmacotherapy; 1997; 17(5):1023-6. PubMed ID: 9324192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of fluconazole after oral administration of single and multiple doses in African grey parrots.
    Flammer K; Papich M
    Am J Vet Res; 2006 Mar; 67(3):417-22. PubMed ID: 16506902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of fluconazole in loggerhead sea turtles (Caretta caretta) after single intravenous and subcutaneous injections, and multiple subcutaneous injections.
    Mallo KM; Harms CA; Lewbart GA; Papich MG
    J Zoo Wildl Med; 2002 Mar; 33(1):29-35. PubMed ID: 12216790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin.
    Mulchahey JJ; Goldwater DR; Zemlan FP
    Life Sci; 2004 Aug; 75(15):1843-56. PubMed ID: 15302228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety.
    Gardin A; Kucher K; Kiese B; Appel-Dingemanse S
    Drug Metab Dispos; 2009 Apr; 37(4):827-33. PubMed ID: 19144772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
    Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
    Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Lasseter KC; Shaughnessy L; Cummings D; Pezzullo JC; Wargin W; Gagnon R; Oliva J; Kosutic G
    J Clin Pharmacol; 2008 Feb; 48(2):193-202. PubMed ID: 18199894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.